Search - tctmd.com

Displaying 801 - 820 of 3290

Sort: Relevancy | Date

COVID-19: TCTMD’s Dispatch for October Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 3

October 18, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

HF Care Didn’t Suffer as Clinicians Turned to Telehealth in COVID-19

News Daily News

HF Care Didn’t Suffer as Clinicians Turned to Telehealth in COVID-19

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

COVID-19: TCTMD’s Dispatch for October Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 2

October 11, 2021

Diabetes Progression in Statin-Treated Patients: VA Data

News Daily News

Diabetes Progression in Statin-Treated Patients: VA Data

Michael O'Riordan

October 06, 2021

SWEDEHEART Data Reassure on 10-Year Survival for TAVI Patients With Pacemakers

News Daily News

SWEDEHEART Data Reassure on 10-Year Survival for TAVI Patients With Pacemakers

October 05, 2021

Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs

News Daily News

Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs

Michael O'Riordan

October 01, 2021

TCTMD’s Top 10 Most Popular Stories for September 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

October 01, 2021

Vasopressor/Steroid Combo Jump-starts Circulation for In-Hospital Cardiac Arrests

News Daily News

Vasopressor/Steroid Combo Jump-starts Circulation for In-Hospital Cardiac Arrests

September 30, 2021

TAVI Is Broadening the Treatable AS Population, Not Cutting Into SAVR

News Daily News

TAVI Is Broadening the Treatable AS Population, Not Cutting Into SAVR

September 30, 2021

Women Stand to Gain the Most From Standardized STEMI Protocols

News Daily News

Women Stand to Gain the Most From Standardized STEMI Protocols

Michael O'Riordan

September 30, 2021

High Burden of CAD in Chest Pain Patients With ‘Normal’ Troponin

News Daily News

High Burden of CAD in Chest Pain Patients With ‘Normal’ Troponin

Michael O'Riordan

September 27, 2021

COVID-19: TCTMD’s Dispatch for September Week 5

News Daily News

COVID-19: TCTMD’s Dispatch for September Week 5

September 27, 2021

In Adults, CV Pathology Dominates COVID-19 Multisystem Inflammatory Syndrome

News Daily News

In Adults, CV Pathology Dominates COVID-19 Multisystem Inflammatory Syndrome

September 23, 2021

Score May Help Guide VITT Management After COVID-19 Vaccination

News Daily News

Score May Help Guide VITT Management After COVID-19 Vaccination

September 23, 2021

AHA Stresses Benefit of Meds, Surgery for Obesity-Related Hypertension

News Daily News

AHA Stresses Benefit of Meds, Surgery for Obesity-Related Hypertension

Yael L. Maxwell

September 23, 2021

Coronary Revascularization Benefits Even Latecomer STEMI: FAST-MI Registry

News Daily News

Coronary Revascularization Benefits Even Latecomer STEMI: FAST-MI Registry

Michael O'Riordan

September 21, 2021

Cardiogenic Shock Teams May Lower Mortality in Cardiac ICUs

News Daily News

Cardiogenic Shock Teams May Lower Mortality in Cardiac ICUs

September 21, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.